Trade Aridis Pharmaceuticals, Inc. - ARDSus CFD

Aridis Pharmaceuticals, Inc. Company profile

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The Company's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Aridis Pharmaceuticals Inc revenues decreased 45% to $548K. Net loss applicable to common stockholders increased from $16.5M to $37.5M. Revenues reflect License revenue decrease of 87% to $131K. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $28.9M (expense), General and administrative - Balancing increase of 11% to $4.1M (expense).